SuperworthKyverna Therapeutics EPS KYTX
Diluted earnings per share by quarter and over the last twelve months, from 2023.
- Last 12 months, to Jun 30, 2026
- −$2.94
- Latest quarter, Q2 FY26
- −$0.63
- Fiscal year 2025
- −$3.65
Kyverna Therapeutics' earnings per share was −$2.94 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.63.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$3.65 | n/a |
| FY2024 | −$3.46 | n/a |
| FY2023 | −$82.22 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.63 | n/a | −$2.94 | |
| Q1 FY26 | −$0.66 | n/a | −$3.28 | |
| Q4 FY25 | −$0.80 | n/a | −$3.65 | |
| Q3 FY25 | −$0.85 | n/a | −$3.72 | |
| Q2 FY25 | −$0.97 | n/a | −$3.67 | |
| Q1 FY25 | −$1.03 | n/a | −$3.37 | |
| Q4 FY24 | −$0.87 | n/a | −$3.46 | |
| Q3 FY24 | −$0.80 | n/a | −$28.58 | |
| Q2 FY24 | −$0.67 | n/a | −$51.05 | |
| Q1 FY24 | −$1.12 | n/a | −$71.24 | |
| Q4 FY23 | −$25.99 | n/a | −$82.22 | |
| Q3 FY23 | −$23.27 | n/a | n/a |
Against its peers
Companies in Biotechnology nearest Kyverna Therapeutics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| KYTXKyverna Therapeutics | −$2.94 | |
| PLXProtalix BioTherapeutics | $0.23 | +283% a year |
| MGTXMeiraGTx | $0.71 | |
| VCELVericel | $0.46 | +283% a year |
| ADMAAdma Biologics | $0.70 | −18% a year |
| Peer median | $0.58 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Kyverna Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.